Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Immuron Reports Double‑Digit Q3 Sales Growth for Travelan
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
SCNX
Scienture Holdings, Inc.
SCNX references Ready-to-Use Pre-Filled Syringe Formulations for injectable therapies, a product-format related tag.
|
$6.94M |
$0.44
-1.77%
|
|
ACUT
Accustem Sciences Inc.
Company plans to offer Laboratory Testing & Advisory Services leveraging existing lab infrastructure and additional sequencing/heritage panels.
|
$6.93M |
$0.43
|
|
TNON
Tenon Medical, Inc.
Catamaran SI Joint Fusion System and related SI implants are orthopedic devices sold as implants for sacroiliac fusion.
|
$6.90M |
$0.80
-1.72%
|
|
HSCS
HeartSciences Inc.
HeartSciences develops medical devices (wavECG) and biometric sensing capabilities, aligning with Medical Devices & Biometrics.
|
$6.83M |
$2.10
+2.18%
|
|
NVNO
enVVeno Medical Corporation
NVNO designs and manufactures medical devices, including implantable bioprosthetic venous valves and related biometrics/sensing technology.
|
$6.76M |
$11.70
+2.09%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$6.67M |
$1.44
-1.03%
|
|
ICU
SeaStar Medical Holding Corporation
Core product is a blood purification device (SCD) used in critical care to modulate immune response and remove inflammatory mediators, fitting Blood Purification Devices.
|
$6.64M |
$2.36
-0.84%
|
|
BMRA
Biomerica, Inc.
Biomerica directly manufactures diagnostic tests (inFoods IBS, hpdetect) and related software/equipment.
|
$6.58M |
$2.20
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$6.56M |
$0.85
+1.50%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$6.37M |
$2.42
+3.86%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$6.33M |
$0.89
-1.61%
|
|
ALUR
Allurion Technologies Inc.
Allurion Balloon is a swallowable medical device used for weight management.
|
$6.21M |
$0.68
-11.17%
|
|
MODV
ModivCare Inc.
MODV delivers technology-enabled healthcare services (NEMT, PCS, Monitoring) and related care operations, aligning with Healthcare Services & Facilities.
|
$6.19M |
$0.43
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$6.14M |
$1.07
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$6.09M |
$0.45
-5.73%
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.03M |
$5.04
+0.80%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$5.94M |
$2.66
+1.14%
|
|
LUDG
Ludwig Enterprises, Inc.
Development of non-invasive diagnostic tests/biomarker-based technology qualifies as medical devices & biometrics.
|
$5.69M |
$0.04
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$5.62M |
$0.76
+0.68%
|
|
EVTV
Envirotech Vehicles, Inc.
Medical Device Consumables: Medical supplies segment with related-party sales and cost-plus pricing indicating consumable offerings.
|
$5.61M |
$1.51
-5.03%
|
|
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
The company operates a software-driven planning/diagnostic workflow used in radiology/medical imaging, which can be associated with the diagnostic equipment category.
|
$5.61M |
$0.88
+212.47%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$5.60M |
$0.95
+12.38%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$5.49M |
$0.84
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$5.47M |
$1.17
-4.88%
|
|
LQMT
Liquidmetal Technologies, Inc.
Medical Device Components: Liquidmetal designs/manufactures customized components for medical devices using its amorphous alloys.
|
$5.41M |
$0.13
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$5.34M |
$0.90
+2.67%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$5.29M |
$7.29
+7.05%
|
|
ALBT
Avalon GloboCare Corp.
KetoAir breathalyzer is a directly produced diagnostic equipment device sold as a precision diagnostic product.
|
$5.14M |
$1.06
-20.52%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.07M |
$1.55
-0.26%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$5.05M |
$0.19
-0.32%
|
|
CRVW
CareView Communications, Inc.
CareView's core offering is patient monitoring via video-based systems, including SitterView and TeleMedView components.
|
$4.99M |
$0.04
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$4.96M |
$2.37
-4.82%
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$4.94M |
$5.46
-2.67%
|
|
INBS
Intelligent Bio Solutions Inc.
INBS directly develops and sells the Intelligent Fingerprinting Platform, a diagnostic device for non-invasive drug screening (fingerprint sweat-based testing) and associated cartridges/readers.
|
$4.94M |
$5.97
+8.55%
|
Showing page 35 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
